

Review of: "Targeting Alzheimer's disease hallmarks with the Nrf2 activator Isoeugenol"

Mahtab Sayadi¹

¹ Birjand University of Medical Sciences

Potential competing interests: No potential competing interests to declare.

Considering the increasing importance of finding a suitable treatment for Alzheimer's disease, the article has an interesting idea and it seems that the design and implementation of this research was appropriate and scientific.

1. in abstract mention AD for first time in Parentheses.
2. introduction is too long and in final paragraph it recommended to mention the hypothesis behind the research clearly.
3. in "Blanks (without the addition of the enzyme and substrate and with Iso)" sentence, why you eliminate both enzyme and substrate instead of only one of them?
4. in " β -Secretase Inhibitor IV (Calbiochem, Merck KGaA, Darmstadt, Germany) was used as a reference inhibitor at its IC₅₀ concentration (15 nM) to validate the procedure." part, how IC₅₀ was calculated?
5. in part 2.2.4.1, "The aliquoted samples were stored at -80 °C until their use" is unclear, which samples?
6. why did you choose different materials for anesthetizing?
7. why you choose different internal controls in every single western blot test?
8. In fig 4, statistical significance did not shown.